Table 3.

Five-Year Actuarial Estimate of Disease-Free Survival and Cumulative Incidences of Relapse and Nonrelapse Mortality and Univariate P for Patients With Previously Untreated Secondary AML

Patient CategoryNo.Disease-Free SurvivalRelapseNonrelapse Mortality
%P%P%P
All untreated patients 46 24.4  31.3  44.3 
Discrete variables: 
PB blasts at SCT3-150 
0-3.0 (×109 cells/L) 16 31.3  18.8  50.0 
3.1-5.5 (×109 cells/L) 15 32.0 .676 21.3 .919 46.7 .667 
>5.5 (×109 cells/L) 15 20.0 .224 53.3 .034 46.7 .702 
Disease etiology 
MDS-related 29 34.5  24.1  41.4 
Therapy-related 17 7.8 .159 43.1 .160 49.0 .516 
Patient age 
<40 yrs 22 31.8  36.4  31.8 
≥40 yrs 24 14.6 .335 28.1 .780 57.3 .142 
Donor 
Genotypic match 30 27.5  31.3  41.3 
Nongenotypic match 16 18.8 .432 31.3 .728 50.0 .464 
Preparative regimen 
Chemo only or Cy + ≤14.4 Gy TBI3-151 28 19.1  40.5  40.5 
15.75 Gy TBI or Bu-Cy-TBI3-152 18 33.3 .382 16.7 .116 50.0 .817 
Continuous variables: 
Peripheral blood blasts at SCT   .111  .050  .677 
Patient age   .152  .802  .096 
Disease duration   .137  .352  .245 
Time from MDS diagnosis to AML diagnosis   .212  .374  .371 
Time from AML diagnosis to SCT   .026  .659  .020 
Hematocrit at time of SCT   .415  .525  .593 
Neutrophil count at time of SCT   .087  .045  .607 
Platelet count at time of SCT   .104  .320  .198 
Patient CategoryNo.Disease-Free SurvivalRelapseNonrelapse Mortality
%P%P%P
All untreated patients 46 24.4  31.3  44.3 
Discrete variables: 
PB blasts at SCT3-150 
0-3.0 (×109 cells/L) 16 31.3  18.8  50.0 
3.1-5.5 (×109 cells/L) 15 32.0 .676 21.3 .919 46.7 .667 
>5.5 (×109 cells/L) 15 20.0 .224 53.3 .034 46.7 .702 
Disease etiology 
MDS-related 29 34.5  24.1  41.4 
Therapy-related 17 7.8 .159 43.1 .160 49.0 .516 
Patient age 
<40 yrs 22 31.8  36.4  31.8 
≥40 yrs 24 14.6 .335 28.1 .780 57.3 .142 
Donor 
Genotypic match 30 27.5  31.3  41.3 
Nongenotypic match 16 18.8 .432 31.3 .728 50.0 .464 
Preparative regimen 
Chemo only or Cy + ≤14.4 Gy TBI3-151 28 19.1  40.5  40.5 
15.75 Gy TBI or Bu-Cy-TBI3-152 18 33.3 .382 16.7 .116 50.0 .817 
Continuous variables: 
Peripheral blood blasts at SCT   .111  .050  .677 
Patient age   .152  .802  .096 
Disease duration   .137  .352  .245 
Time from MDS diagnosis to AML diagnosis   .212  .374  .371 
Time from AML diagnosis to SCT   .026  .659  .020 
Hematocrit at time of SCT   .415  .525  .593 
Neutrophil count at time of SCT   .087  .045  .607 
Platelet count at time of SCT   .104  .320  .198 
F3-150

The P reported result from comparison with the lowest peripheral blast group.

F3-151

Regimens containing chemotherapy only or containing cyclophosphamide (Cy) and ≤14.4 Gy TBI (see Table 2).

F3-152

Regimens containing Cy + 15.75 Gy or busulfan (or dimethylmyleran) + Cy + 12 Gy TBI (see Table 2).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal